Reducing Risk of Transplantation for People with IgA Nephropathy: What Managed Care Pharmacists Can Do To Help Optimize Treatment
Join an expert nephrologist and pharmacist to discuss these new and emerging treatment options, up-to-date evidence on their safety and efficacy, and recommendations from practice guidelines. Managed care pharmacists will be prepared to enhance access to these beneficial treatments and include them in medication-management programs for appropriate patients with IgAN.
Learning Objectives:
- Describe the burden of IgAN and the inability of current treatment approaches to reduce risk of transplantation.
- Summarize data supporting the efficacy and safety of dual inhibition of RAS and endothelin-1 to reduce proteinuria and slow kidney-function decline in those with IgAN more than RAS inhibition alone does.
- Recognize the place of dual inhibitors of RAS and endothelin-1 to treat IgAN, delay risk of transplantation, and reduce overall cost of care.
Speakers:
Rosanna Coppo, MD, FERA
Nephrologist
Fondazione Ricerca Molinette
Regina Margherita Hospital
Michelle M. Richardson, PharmD
Special and Scientific Staff
William B. Schwartz Division of Nephrology
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
This activity is supported by an educational grant from Travere Therapeutics.
